Fig. 5

LCN2 concentrations 9 months off-SLIT are higher in subjects whose symptoms ameliorated. (a) LCN2-concentration after end of treatment and (b) individual relative improvement of the total nasal symptom score, TNSS, in the active and placebo-treated groups. The threshold of 20% for amelioration of symptoms (grey area) were set to group study participants according to their clinical outcome. (c) LCN2-concentrations 9 months off-SLIT of patients according to their clinical outcome, irrespective whether the subjects belonged to the placebo- or active treated group. (d) Correlation of absolute LCN2-levels 9 month off-SLIT with subjects’ relative improvement in the TNSS. Statistical analyses were conducted using one-way ANOVA using Tukey’s multiple comparisons test for post-hoc analyses. Correlation was obtained using Pearson’s rank method